Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price, News & Analysis

CTI BioPharma logo

About CTI BioPharma Stock (NASDAQ:CTIC)

Key Stats

Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Q1 2024 Veracyte Inc Earnings Call
Connect Biopharma Holdings Ltd (CNTB)
Theravance Biopharma Inc TBPH
CTI Engineering Co Ltd (9621)
See More Headlines

CTIC Stock Analysis - Frequently Asked Questions

CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analyst estimates of $24.88 million.

CTI BioPharma shares reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/06/2023
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
127
Year Founded
1992

Profitability

Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:CTIC) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners